Porcilis PCV
Active substance
ATC code
Species
Pigs.
Indications
For the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce mortality and weight loss associated with PCV2 infection occurring during the fattening period.
Onset of immunity: 2 weeks.
Duration of immunity: 22 weeks.
Dose to be administered and administration route
Before using the vaccine, allow it to reach room temperature and shake well before use. Avoid multiple vial broaching. Use sterile syringes and needles. Avoid introduction of contamination. Avoid use of vaccination equipment with rubber parts.
Vaccination
Administer one dose of 2 ml by intramuscular injection in the neck, in the area behind the ear, according to the following schedule:
In the case of low to medium levels of maternally derived antibodies against PCV2 a single vaccination (2 ml) to pigs from an age of 3 weeks onwards is advised.
When it is expected that higher levels of maternally derived antibodies against PCV2 are present, the following schedule of two vaccinations is advised: the first injection (2 ml) can be given from an age of 3 – 5 days, the second injection (2 ml) 2 – 3 weeks later.
High levels of MDA may be expected when sows/gilts are vaccinated against PCV2 virus or when sows/gilts have recently been exposed to high levels of PCV2 virus. In such cases it is advised to perform PCV2 serology, using suitable diagnostics, to select the most appropriate vaccination schedule. In case of doubt, apply the two shot vaccination schedule.
Adverse reactions
Pigs:
|
Very common (>1 animal / 10 animals treated): |
Injection site swelling1, Elevated temperature2. |
|
Common (1 to 10 animals / 100 animals treated): |
Hypersensitivity reaction3. |
|
Uncommon (1 to 10 animals / 1,000 animals treated): |
Elevated temperature4, Depression5, Reduced food intake5. |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Anaphylactic-type reaction6. |
1 In the form of a hard, warm and sometimes painful swelling (diameter up to 10 cm). These reactions resolve spontaneously over a period of approximately 14 – 21 days without any major consequence on the general health status of the animals.
2 Normally not exceeding 1 °C, observed until 2 days after vaccination.
3 Resulting in minor neurological symptoms such as tremors and/or excitation, which normally resolve within minutes without requiring treatment.
4 In individual animals, an increase of rectal temperature of 2.5 °C lasting less than 24 hours.
5 Up to 5 days, may result in transient impairment of growth rate in the immediate period after the administration of the vaccine.
6 May be life-threatening. In the event of such reactions, treatment may be needed.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for contact details.
TRUSTED SOURCE
